[Special Stock] ABL Bio Benefits from SK Biopharm IPO... Discussing Technology Transfers with 15 Big Pharma Companies

[Asia Economy Reporter Hyungsoo Park] ABL Bio is soaring.

At 11:19 a.m. on the 16th, ABL Bio was trading at 30,950 won, up 18.81% from the previous day.

Korea Investment & Securities expressed the opinion that interest in ABL Bio (hereinafter ABL) could increase following the domestic listing of SK Biopharm, which developed two brain disease treatments.

Jinhongguk, a researcher at Korea Investment & Securities, said, "The listing of SK Biopharm, which launched two brain disease treatments in the U.S., will serve as an opportunity to confirm the potential of brain disease treatment developers," adding, "Attention to brain disease treatment companies including ABL is necessary."

ABL (ABL-301) targets alpha-synuclein, the cause of Parkinson's disease. Although it is in the preclinical stage, it has advantages such as excellent safety, a long half-life, and easy implementation through animal models, and is currently discussing technology transfers with about 15 global top 20 big pharma partners. It is expected to achieve platform technology transfer results in the second half of the year.

The brain disease treatment market size was $84 billion as of 2018, ranking third after anticancer drugs ($124 billion) and infectious diseases ($96 billion).

Researcher Jinhongguk said, "Recently, platform companies such as Alteogen, Cellivery, and LegoChem Bio have seen sharp stock price increases," adding, "This is because the platform nature is recognized for the possibility of repeated technology exports."

ABL possesses three platforms: GrabodyT, Grabody I, and Grabody B, and the company already has experience with five technology exports totaling 1.4 trillion won. On the 22nd, ABL will reveal research results of four pipelines at the American Association for Cancer Research (AACR). Also, ABL-001, which was in clinical phase 1a, is preparing to enter phases 1b/2.

Researcher Jin forecasted, "With a favorable development environment and visible achievements, ABL's corporate value will increase further."

This content was produced with the assistance of AI translation services.